Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 2:19 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 913–936 of 3,097 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: MCG Clear all
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Sanofi Pasteur, TIV + H1N1, Pediatric Population

NCT00943202
View directory record Official record
Conditions
Influenza
Interventions
Inactivated H1N1 Vaccine, Trivalent Inactivated Influenza Vaccine
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
6 Months to 17 Years
Enrollment
531 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
8
States / cities
Atlanta, Georgia • Iowa City, Iowa • St Louis, Missouri + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 22, 2013 · Synced Oct 30, 2026, 2:19 PM EDT
Not listed Early Phase 1 Interventional

Pain Control and Quality of Recovery After Intravenous Methadone Versus Intrathecal Morphine in Major Abdominal Surgery

NCT06387303
View directory record Official record
Conditions
Pain, Postoperative
Interventions
Methadone, Morphine
Drug
Lead sponsor
University of Virginia
Other
Eligibility
18 Years to 75 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Aug 11, 2025 · Synced Oct 30, 2026, 2:19 PM EDT
Recruiting Not applicable Interventional

Music Listening: A Mechanistic Trial

NCT05541029
View directory record Official record
Conditions
Critical Illness
Interventions
Live music, Recorded music, Usual care
Behavioral · Other
Lead sponsor
University of Pittsburgh
Other
Eligibility
2 Months to 17 Years
Enrollment
171 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 20, 2026 · Synced Oct 30, 2026, 2:19 PM EDT
Terminated Phase 2 Interventional Results available

Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Multiple Dose Regimens of MT-3724 With Lenalidomide for the Treatment of Participants With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (MT-3724_NHL_003)

NCT03645395
View directory record Official record
Conditions
Non-hodgkin Lymphoma
Interventions
MT-3724
Drug
Lead sponsor
Molecular Templates, Inc.
Industry
Eligibility
18 Years to 101 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
5
States / cities
Whittier, California • Plantation, Florida • Chicago, Illinois + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 16, 2022 · Synced Oct 30, 2026, 2:19 PM EDT
Recruiting Early Phase 1 Interventional

Induction of Labor in Morbidly Obese Patients

NCT06199154
View directory record Official record
Conditions
Morbid Obesity, Pregnancy
Interventions
Misoprostol
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years and older · Female only
Enrollment
162 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Oct 30, 2026, 2:19 PM EDT
Completed Phase 2 Interventional Results available

A Study of Flovent in Patients With Eosinophilic Esophagitis

NCT00426283
View directory record Official record
Conditions
Eosinophilic Esophagitis
Interventions
Flovent, Placebo
Drug · Other
Lead sponsor
Marc Rothenberg, MD
Other
Eligibility
3 Years to 30 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
4
States / cities
Aurora, Colorado • Cincinnati, Ohio • Philadelphia, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2020 · Synced Oct 30, 2026, 2:19 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Diesel Exhaust and Vascular Function

NCT01508637
View directory record Official record
Conditions
Cardiovascular Effects
Interventions
Diesel Exhaust, Filtered Air, Terazosin, placebo
Other · Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 49 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2015
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Aug 3, 2015 · Synced Oct 30, 2026, 2:19 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Immunogenicity of a Live Attenuated H7N9 Influenza Virus Vaccine in Healthy Adults

NCT01995695
View directory record Official record
Conditions
Influenza A Virus, H7N9 Subtype
Interventions
Live attenuated H7N9 A/Anhui/13 ca influenza virus vaccine, Inactivated subvirion H7N9 influenza vaccine
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 49 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2013
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Jul 27, 2016 · Synced Oct 30, 2026, 2:19 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Plerixafor and Clofarabine in Frontline Treatment of Elderly Patients With Acute Myelogenous Leukemia (AML)

NCT01160354
View directory record Official record
Conditions
Acute Myelogenous Leukemia
Interventions
Plerixafor, Clofarabine
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
60 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 28, 2019 · Synced Oct 30, 2026, 2:19 PM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Safety and Efficacy of CR845 in Hemodialysis Patients With Moderate-to-Severe Pruritus (KALM-1)

NCT03422653
View directory record Official record
Conditions
Uremic Pruritus
Interventions
CR845 0.5 mcg/kg, Placebo
Drug
Lead sponsor
Cara Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
378 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
57
States / cities
Homewood, Alabama • Huntsville, Alabama • Bakersfield, California + 52 more
Source: ClinicalTrials.gov public record
Updated Apr 26, 2022 · Synced Oct 30, 2026, 2:19 PM EDT
Recruiting Phase 4 Interventional

Postpartum Vaginal Estrogen for Breastfeeding Patients

NCT05457972
View directory record Official record
Conditions
Breastfeeding, Postpartum Sexual Dysfunction, Vaginal Atrophy
Interventions
Estradiol, Vaginal Moisturizer
Drug · Device
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 23, 2026 · Synced Oct 30, 2026, 2:19 PM EDT
Completed Phase 1 Interventional

Combination Therapy of Topical Imiquimod Plus Multipeptide Vaccination for Cutaneous Metastases of Melanoma

NCT01264731
View directory record Official record
Conditions
Melanoma
Interventions
MELITAC 12.1, Imiquimod
Biological · Drug
Lead sponsor
University of Virginia
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Dec 16, 2016 · Synced Oct 30, 2026, 2:19 PM EDT
Completed Phase 3 Interventional Results available

An Efficacy, Safety, and Tolerability Study of TMC435 in Treatment-naive, Genotype 1 Hepatitis C-infected Participants

NCT01290679
View directory record Official record
Conditions
Hepatitis C
Interventions
Placebo, TMC435, Peginterferon alpha-2a or Peginterferon alpha-2b (PegIFNα-2a/b), Ribavirin (RBV)
Drug
Lead sponsor
Janssen R&D Ireland
Industry
Eligibility
18 Years and older
Enrollment
393 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
11
States / cities
Los Angeles, California • Jacksonville, Florida • Orlando, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Jun 13, 2014 · Synced Oct 30, 2026, 2:19 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Safety, Tolerability, and Immunogenicity Study of a 31-Valent Pneumococcal Conjugate Vaccine (VAX-31) in Adults

NCT06151288
View directory record Official record
Conditions
Pneumococcal Vaccines
Interventions
31 valent pneumococcal conjugate vaccine, 20 valent pneumococcal conjugate vaccine
Biological
Lead sponsor
Vaxcyte, Inc.
Industry
Eligibility
50 Years and older
Enrollment
1,015 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
25
States / cities
Mobile, Alabama • Phoenix, Arizona • Hollywood, Florida + 22 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2025 · Synced Oct 30, 2026, 2:19 PM EDT
Completed Phase 3 Interventional Results available

A Study to Assess the Efficacy and Safety of Budesonide/Albuterol Metered Dose Inhaler (BDA MDI/PT027) Used 4 Times Daily in Adults and Children 4 Years of Age or Older With Asthma

NCT03847896
View directory record Official record
Conditions
Asthma
Interventions
Budesonide/albuterol sulfate metered dose inhaler / BDA MDI 160/180 μg (high dose), Budesonide/albuterol sulfate metered dose inhaler / BDA MDI 80/180 μg (low dose), Budesonide metered dose inhaler / BD MDI 160 µg, Albuterol sulfate metered dose inhaler / AS MDI 180 μg, Placebo metered-dose inhaler / Placebo MDI
Combination Product · Drug · Other
Lead sponsor
Bond Avillion 2 Development LP
Industry
Eligibility
4 Years and older
Enrollment
1,001 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
73
States / cities
Mobile, Alabama • Bakersfield, California • Costa Mesa, California + 60 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2023 · Synced Oct 30, 2026, 2:19 PM EDT
Not yet recruiting No phase listed Observational Accepts healthy volunteers

Hand Perfusion and Pulse Oximetry Performance

NCT06925646
View directory record Official record
Conditions
Oxygen Saturation
Interventions
Finger hyperperfusion via adenosine, Finger hypoperfusion via by norepinephrine, Baseline hypoxic test
Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 13, 2026 · Synced Oct 30, 2026, 2:19 PM EDT
Not listed Early Phase 1 Interventional Accepts healthy volunteers

Relative Contributions of Predictors of Hyperandrogenism in Older vs. Young Women With PCOS

NCT03905603
View directory record Official record
Conditions
Polycystic Ovary Syndrome
Interventions
ACTH, rhCG
Drug
Lead sponsor
University of Virginia
Other
Eligibility
20 Years to 49 Years · Female only
Enrollment
144 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2026
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Nov 3, 2023 · Synced Oct 30, 2026, 2:19 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

KEEPS Mammographic Density And Breast Health Ancillary Study

NCT02524561
View directory record Official record
Conditions
Mammographic Density, Abnormal Mammogram
Interventions
CEE pill, Estradiol patch, Active Progesterone, Placebo tablet, Placebo patch, Placebo progesterone
Drug · Other
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
42 Years to 58 Years · Female only
Enrollment
517 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2013
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 8, 2017 · Synced Oct 30, 2026, 2:19 PM EDT
Completed Phase 4 Interventional

Postoperative Pain Control With Fentanyl Patch in Patients Undergoing Mastectomy and TRAM or DIEP Flap Reconstruction

NCT01258296
View directory record Official record
Conditions
Postoperative Pain After Breast Reconstruction With Abdominal Flap
Interventions
Fentanyl, Inactive patch
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older · Female only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Dec 12, 2023 · Synced Oct 30, 2026, 2:19 PM EDT
Terminated Phase 1Phase 2 Interventional

Safety and Efficacy Study in the Treatment of Pediatric Crohn's Disease

NCT00206661
View directory record Official record
Conditions
Crohn Disease
Interventions
Sargramostim (Leukine)
Drug
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
6 Years to 16 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
7
States / cities
San Francisco, California • Atlanta, Georgia • New Orleans, Louisiana + 4 more
Source: ClinicalTrials.gov public record
Updated Dec 4, 2013 · Synced Oct 30, 2026, 2:19 PM EDT
Completed Phase 3 Interventional Results available

A Study of Pegylated Interferon Alfa-2A in Combination With Lamivudine or Entecavir Compared With Untreated Control Group in Children With Hepatitis B Envelope Antigen (HBeAg)-Positive Chronic Hepatitis B (CHB) in the Immune-Tolerant Phase

NCT02263079
View directory record Official record
Conditions
Pediatric Immuno-Tolerant Chronic Hepatitis B
Interventions
Entecavir, Lamivudine, Pegylated Interferon Alfa-2A
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
3 Years to 17 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
3
States / cities
Kansas City, Missouri • New York, New York • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 24, 2020 · Synced Oct 30, 2026, 2:19 PM EDT
Completed Phase 2 Interventional Results available

A Trial of Poly-ICLC in the Management of Recurrent Pediatric Low Grade Gliomas

NCT01188096
View directory record Official record
Conditions
Brain Tumors
Interventions
Poly ICLC
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
Up to 21 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2019
U.S. locations
2
States / cities
San Diego, California • Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jun 12, 2023 · Synced Oct 30, 2026, 2:19 PM EDT
Completed Phase 4 Interventional Results available

Study to Evaluate the Safety of Long-Term Use of Perforomist® (Formoterol Fumarate)

NCT01488019
View directory record Official record
Conditions
COPD
Interventions
Perforomist-Placebo, Perforomist, nebulization, COPD
Drug
Lead sponsor
Dey
Industry
Eligibility
40 Years and older
Enrollment
1,071 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Greenville, South Carolina
Source: ClinicalTrials.gov public record
Updated Jun 12, 2017 · Synced Oct 30, 2026, 2:19 PM EDT
Terminated Phase 1 Interventional Results available

A Phase I, Multicenter, Dose Escalation Study of CAT-8015 in Participants With Chronic Leukemia

NCT00587457
View directory record Official record
Conditions
Leukemia, Lymphoma, Chronic Lymphocytic, Leukemia, Prolymphocytic Leukemia, Small, Lymphocytic Lymphoma, Moxetumomab Pasudotox
Interventions
CAT-8015 5 mcg/kg, CAT-8015 10 mcg/kg, CAT-8015 20 mcg/kg
Drug
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
2
States / cities
Indianapolis, Indiana • Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 6, 2017 · Synced Oct 30, 2026, 2:19 PM EDT